Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFLY Butterfly Network	$1.39 +1.8%	$1.94	$0.90 ▼ $4.98	$342.37M	2.45	3.87 million shs	2.52 million shs
MGNX MacroGenics	$1.47	$1.51	$0.99 ▼ $5.10	$92.74M	1.65	637,553 shs	434,777 shs
NUVB Nuvation Bio	$2.32 +3.6%	$2.20	$1.54 ▼ $3.45	$762.19M	1.35	4.20 million shs	4.26 million shs
SMTI Sanara MedTech	$27.47 +2.3%	$27.58	$23.53 ▼ $39.08	$238.73M	1.26	44,768 shs	36,352 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFLY Butterfly Network	+2.25%	-4.21%	-24.59%	-42.65%	+41.39%
MGNX MacroGenics	-4.55%	-10.37%	-8.70%	-4.55%	-58.24%
NUVB Nuvation Bio	-2.83%	-3.25%	+1.59%	+2.05%	-21.02%
SMTI Sanara MedTech	+8.31%	+8.48%	-7.57%	-23.48%	-3.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFLY Butterfly Network	2.1567 of 5 stars	3.4	1.0	0.0	2.3	2.5	0.6
MGNX MacroGenics	4.4051 of 5 stars	3.3	4.0	4.4	2.6	2.5	0.6
NUVB Nuvation Bio	1.9479 of 5 stars	3.6	0.0	0.0	2.4	3.3	0.0
SMTI Sanara MedTech	2.062 of 5 stars	3.5	1.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFLY Butterfly Network	2.75	Moderate Buy	$3.00	116.61% Upside
MGNX MacroGenics	2.57	Moderate Buy	$5.40	267.35% Upside
NUVB Nuvation Bio	3.17	Buy	$7.33	216.09% Upside
SMTI Sanara MedTech	3.00	Buy	$49.50	80.20% Upside

Current Analyst Ratings Breakdown

Latest BFLY, NUVB, SMTI, and MGNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
8/4/2025	BFLY Butterfly Network	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Positive ➝ Positive	$2.00
8/1/2025	BFLY Butterfly Network	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/1/2025	BFLY Butterfly Network	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/2/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/15/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $5.00
5/15/2025	SMTI Sanara MedTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$51.00 ➝ $53.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFLY Butterfly Network	$82.06M	4.25	N/A	N/A	$0.92 per share	1.51
MGNX MacroGenics	$149.96M	0.62	N/A	N/A	$1.85 per share	0.79
NUVB Nuvation Bio	$7.87M	100.31	N/A	N/A	$1.10 per share	2.11
SMTI Sanara MedTech	$86.67M	2.82	N/A	N/A	$4.45 per share	6.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFLY Butterfly Network	-$72.49M	-$0.28	N/A	N/A	N/A	-71.79%	-30.53%	-21.80%	N/A
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/12/2025 (Estimated)
NUVB Nuvation Bio	-$567.94M	-$0.63	N/A	N/A	N/A	-1,413.43%	-46.14%	-36.04%	N/A
SMTI Sanara MedTech	-$9.66M	-$1.34	N/A	N/A	N/A	-12.48%	-29.22%	-13.20%	8/13/2025 (Estimated)

Latest BFLY, NUVB, SMTI, and MGNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SMTI Sanara MedTech	-$0.33	N/A	N/A	N/A	$25.15 million	N/A
8/12/2025	Q2 2025	MGNX MacroGenics	-$0.59	N/A	N/A	N/A	$28.06 million	N/A
8/7/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	-$0.17	N/A	-$0.17	$0.42 million	$4.83 million
8/1/2025	Q2 2025	BFLY Butterfly Network	-$0.07	-$0.06	+$0.01	-$0.06	$23.91 million	$23.38 million
5/14/2025	Q1 2025	SMTI Sanara MedTech	-$0.31	-$0.41	-$0.10	-$0.41	$23.48 million	$23.43 million
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFLY Butterfly Network	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
SMTI Sanara MedTech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFLY Butterfly Network	N/A	5.68	4.14
MGNX MacroGenics	N/A	3.28	3.11
NUVB Nuvation Bio	0.13	9.39	9.38
SMTI Sanara MedTech	1.18	2.77	2.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFLY Butterfly Network	37.85%
MGNX MacroGenics	96.89%
NUVB Nuvation Bio	61.67%
SMTI Sanara MedTech	8.10%

Insider Ownership

Company	Insider Ownership
BFLY Butterfly Network	25.18%
MGNX MacroGenics	13.00%
NUVB Nuvation Bio	29.93%
SMTI Sanara MedTech	42.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFLY Butterfly Network	460	251.74 million	188.35 million	Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable
SMTI Sanara MedTech	60	8.89 million	5.10 million	Not Optionable

BFLY, NUVB, SMTI, and MGNX Headlines

Recent News About These Companies

Sanara MedTech Inc (SMTI) Q2 2025: Everything You Need To Know Ahead Of Earnings

4 hours ago | finance.yahoo.com

Sanara MedTech (SMTI) Projected to Post Quarterly Earnings on Wednesday

August 12 at 2:21 AM | americanbankingnews.com

Sanara MedTech (NASDAQ:SMTI) investors are sitting on a loss of 12% if they invested three years ago

August 10 at 1:36 PM | finance.yahoo.com

Sanara MedTech (SMTI) to Release Earnings on Wednesday

August 6, 2025 | marketbeat.com

Sanara MedTech (NASDAQ:SMTI) Stock Price Down 1.5% - Here's Why

July 18, 2025 | marketbeat.com

Sanara MedTech to Report Second Quarter 2025 Financial Results on August 13, 2025

July 15, 2025 | globenewswire.com

Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program

July 14, 2025 | globenewswire.com

Sanara MedTech: Pursuing Rapid Expansion While Debt Levels Climb

June 9, 2025 | seekingalpha.com

Sanara MedTech Shares Down, Investors Sought For Pilot Program

May 15, 2025 | marketwatch.com

Earnings call transcript: Sanara Medtech Q1 2025 earnings miss forecasts

May 15, 2025 | investing.com

Earnings call transcript: Sanara Medtech Q1 2025 earnings miss forecasts

May 15, 2025 | investing.com

Sanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

May 15, 2025 | finance.yahoo.com

Sanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

May 15, 2025 | finance.yahoo.com

Sanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

Sanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

Sanara MedTech Inc. (SMTI) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Sanara MedTech Inc. (SMTI) Reports Q1 Loss, Tops Revenue Estimates

May 14, 2025 | zacks.com

Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)

May 14, 2025 | gurufocus.com

Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited) | SMTI Stock News

May 14, 2025 | gurufocus.com

Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)

May 14, 2025 | investing.com

Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)

May 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFLY, NUVB, SMTI, and MGNX Company Descriptions

Butterfly Network NYSE:BFLY

$1.38 +0.03 (+1.84%)

Closing price 03:59 PM Eastern

Extended Trading

$1.42 +0.03 (+2.53%)

As of 08:00 PM Eastern

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

MacroGenics NASDAQ:MGNX

$1.47 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.44 -0.03 (-1.77%)

As of 07:42 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Nuvation Bio NYSE:NUVB

$2.32 +0.08 (+3.57%)

Closing price 03:59 PM Eastern

Extended Trading

$2.35 +0.03 (+1.08%)

As of 07:58 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Sanara MedTech NASDAQ:SMTI

$27.47 +0.61 (+2.27%)

Closing price 04:00 PM Eastern

Extended Trading

$27.45 -0.02 (-0.08%)

As of 07:22 PM Eastern

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time